Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes product candidates across various therapeutic areas, including immunology, oncology, hematology, and dermatology. Its pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis; mosliciguat, an inhaled soluble sGC activator in development for pulmonary hypertension associated with interstitial lung disease, in addition to other clinical-stage molecules; and namilumab, is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor, an inflammatory cytokine involved in inflammatory disorders such as sarcoidosis.